The core transdifferentiation technology platform of Neuregen Therapeutics utilizes safe and efficient delivery vectors to express combinations of transcription factors, thereby achieving multiple cell fate reprogramming events in vivo for therapeutic purposes.
Compared with traditional ex vivo cell reprogramming technologies, the company’s in situ transdifferentiation approach does not pass through a pluripotent stem cell stage, thus avoiding potential risks associated with pluripotency, such as tumorigenicity and immune rejection. Our technology platform has been validated in both in vivo and in vitro models of tumors and neurological diseases, bringing new hope for the effective treatment of these conditions.
Core Technology: In Vivo Cell Reprogramming
